Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated radiotherapy + GM-CSF + lenalidomide + glofitamab in relapsed/refractory DLBCL (Phase II)
ChiCTR2500096963Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Feb 2025
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glofitamab, lenalidomide and granulocyte macrophage-colony stimulating factor in diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoints: Objective response rate (ORR) and Complete remission rate (CR). Planned start Feb 2025; status: not yet recruiting.
02
Drugs
glofitamablenalidomidegranulocyte macrophage-colony stimulating factor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2500096963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096963.